Login / Signup

Combining oncolytic virus with FDA approved pharmacological agents for cancer therapy.

Wei ZhangClark C ChenJiangfang Ning
Published in: Expert opinion on biological therapy (2020)
While the cytolytic activity of OV remains a key driver for its anti-neoplastic effects, understanding the virus-host interactions may afford opportunities for potential synergism with FDA approved therapeutics that target these interactions. Most intriguingly, the immune stimulatory effects of OVs renders combination with FDA approved immunotherapies more potent. While there are growing clinical trials employing such combination therapy, meaningful advances in this paradigm will require improved understanding of virus-host interactions.
Keyphrases
  • combination therapy
  • drug administration
  • cancer therapy
  • clinical trial
  • drug delivery
  • small molecule
  • phase ii
  • anti inflammatory
  • human health
  • study protocol
  • phase iii